Patents by Inventor Yannick Marc

Yannick Marc has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMBINATION COMPRISING A BRAIN AMINOPEPTIDASE A INHIBITOR, A DIURETIC AND A BLOCKER OF THE SYSTEMIC RENIN-ANGIOTENSIN SYSTEM
    Publication number: 20230233492
    Abstract: The present invention relates to a pharmaceutical combination comprising (i) firibastat, (ii) a diuretic and (iii) a blocker of the systemic renin-angiotensin system selected from the group consisting of angiotensin I converting enzyme inhibitors (ACEIs) and angiotensin II receptor type 1 (AT1R) antagonists. Said composition is particularly useful for the treatment of hypertension and related diseases and conditions.
    Type: Application
    Filed: May 5, 2021
    Publication date: July 27, 2023
    Inventors: FABRICE BALAVOINE, CATHERINE LLORENS-CORTES, YANNICK MARC
  • Compounds and compositions comprising the same for treating hypertension or heart failure
    Patent number: 11345658
    Abstract: The present invention relates to compounds, to compositions comprising the same, to methods for preparing the compounds, and the use of these compounds in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: May 31, 2022
    Assignees: QUANTUM GENOMICS, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COLLEGE DE FRANCE
    Inventors: Fabrice Balavoine, Delphine Compere, Mathilde Keck, Yannick Marc, Catherine Llorens-Cortes, Solène E. Boitard
  • COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR TREATING HYPERTENSION OR HEART FAILURE
    Publication number: 20220041548
    Abstract: The present invention relates to compounds, to compositions comprising the same, to methods for preparing the compounds, and the use of these compounds in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.
    Type: Application
    Filed: March 11, 2020
    Publication date: February 10, 2022
    Inventors: FABRICE BALAVOINE, DELPHINE COMPERE, MATHILDE KECK, YANNICK MARC, CATHERINE LLORENS-CORTES, SOLÈNE E. BOITARD
  • Aminopeptidase A inhibitors and pharmaceutical compositions comprising the same
    Patent number: 11192907
    Abstract: The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: December 7, 2021
    Assignees: QUANTUM GENOMICS, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COLLEGE DE FRANCE
    Inventors: Fabrice Balavoine, Delphine Compere, Catherine Llorens-Cortes, Yannick Marc
  • AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
    Publication number: 20210309678
    Abstract: The present invention relates to a novel compound, to a composition comprising the same, to methods for preparing the compound, and the use of this compound in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.
    Type: Application
    Filed: October 25, 2019
    Publication date: October 7, 2021
    Inventors: FABRICE BALAVOINE, DELPHINE COMPERE, CATHERINE LLORENS-CORTES, YANNICK MARC
  • Combination of (3S,3S?) 4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) and a second antihypertensive agent
    Patent number: 10959938
    Abstract: The present invention relates to a pharmaceutical composition comprising, in at least one pharmaceutically acceptable support or vehicle, a combination of (3S,3S?)4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and a second active ingredient selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type I antagonists. Said composition is particularly useful for the treatment of hypertension and related diseases and conditions.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 30, 2021
    Assignee: Quantum Genomics
    Inventors: Catherine Llorens-Cortes, Yannick Marc, Ji Gao-Desliens, Fabrice Balavoine, Lionel Segard
  • COMBINATION OF (3S,3S') 4,4'-DISULFANEDIYLBIS(3-AMINOBUTANE 1-SULFONIC ACID) AND A SECOND ANTIHYPERTENSIVE AGENT
    Publication number: 20150320703
    Abstract: The present invention relates to a pharmaceutical composition comprising, in at least one pharmaceutically acceptable support or vehicle, a combination of (3S,3S?)4,4?-disulfanediylbis(3-aminobutane 1-sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and a second active ingredient selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type I antagonists. Said composition is particularly useful for the treatment of hypertension and related diseases and conditions.
    Type: Application
    Filed: December 21, 2012
    Publication date: November 12, 2015
    Inventors: Catherine Llorens-Cortes, Yannick Marc, Ji Gao-Desliens, Fabrice Balavoine, Lionel Segard